Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
82,514 sq ft facility to host up to 15 biotech companies, fueling the development of next-generation medicines
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Cagrilintide represents a novel approach to obesity management
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
This is Lupin's first product using proprietary Nanomi's technology and has a 180-day CGT exclusivity
Subscribe To Our Newsletter & Stay Updated
